KR102150162B1 - Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof - Google Patents
Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof Download PDFInfo
- Publication number
- KR102150162B1 KR102150162B1 KR1020180122779A KR20180122779A KR102150162B1 KR 102150162 B1 KR102150162 B1 KR 102150162B1 KR 1020180122779 A KR1020180122779 A KR 1020180122779A KR 20180122779 A KR20180122779 A KR 20180122779A KR 102150162 B1 KR102150162 B1 KR 102150162B1
- Authority
- KR
- South Korea
- Prior art keywords
- wild ginseng
- vol
- concentrate
- liquid composition
- active
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 235000020710 ginseng extract Nutrition 0.000 title claims abstract description 53
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 41
- 238000010521 absorption reaction Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 17
- 239000012141 concentrate Substances 0.000 claims abstract description 49
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 22
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 claims abstract description 21
- 241000332371 Abutilon x hybridum Species 0.000 claims abstract description 20
- 241000383638 Allium nigrum Species 0.000 claims abstract description 18
- 235000012907 honey Nutrition 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims description 58
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 57
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 16
- 230000032683 aging Effects 0.000 claims description 12
- 239000004375 Dextrin Substances 0.000 claims description 9
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 238000010025 steaming Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims 9
- 230000003078 antioxidant effect Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 15
- 230000003579 anti-obesity Effects 0.000 abstract description 13
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 240000004371 Panax ginseng Species 0.000 description 49
- 239000000243 solution Substances 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 21
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 20
- 238000002835 absorbance Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 229940089161 ginsenoside Drugs 0.000 description 14
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 230000003178 anti-diabetic effect Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 11
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 150000002215 flavonoids Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 108010028144 alpha-Glucosidases Proteins 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- ZTQSADJAYQOCDD-FDDSVCGKSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O ZTQSADJAYQOCDD-FDDSVCGKSA-N 0.000 description 5
- 102000019280 Pancreatic lipases Human genes 0.000 description 5
- 108050006759 Pancreatic lipases Proteins 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 5
- 229940116369 pancreatic lipase Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 240000002234 Allium sativum Species 0.000 description 4
- ZFAHNWWNDFHPOH-YFKPBYRVSA-N S-allylcysteine Chemical compound OC(=O)[C@@H](N)CSCC=C ZFAHNWWNDFHPOH-YFKPBYRVSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000004611 garlic Nutrition 0.000 description 4
- -1 glycoside compounds Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 2
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZFAHNWWNDFHPOH-UHFFFAOYSA-N S-Allyl-L-cystein Natural products OC(=O)C(N)CSCC=C ZFAHNWWNDFHPOH-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229940107131 ginseng root Drugs 0.000 description 2
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WYQZZUUUOXNSCS-YFKPBYRVSA-N (2r)-2-amino-3-(prop-2-enyldisulfanyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CSSCC=C WYQZZUUUOXNSCS-YFKPBYRVSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical group N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- WYQZZUUUOXNSCS-UHFFFAOYSA-N S-allylmercapto-L-cysteine Natural products OC(=O)C(N)CSSCC=C WYQZZUUUOXNSCS-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940071182 stannate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명에서는 활성산양삼 추출액, 홍삼 농축액, 도라지 농축액, 흑마늘 농축액, 벌꿀을 포함하여, 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이 함량이 현저히 증진되고, 우수한 항산화 활성, 항당뇨 및 항비만 활성을 갖고, 휴대와 먹기가 편리한 스틱형 용기용 액상 조성물이 개시된다.In the present invention, including active wild ginseng extract, red ginseng concentrate, bellflower concentrate, black garlic concentrate, and honey, the human body absorbable ginsenosides Rd2, F2, Rg3 and compound K content are significantly enhanced, excellent antioxidant activity, anti-diabetes and anti-obesity Disclosed is a liquid composition for a stick-shaped container that has activity and is convenient to carry and eat.
Description
본 발명은 인체 흡수형 진세노사이드가 증진된 활성산양삼 추출액을 포함하는 스틱형 용기용 액상 조성물 및 그 제조방법에 관한 것으로, 더 상세하게는 활성산양삼 추출액을 포함하여 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이의 함량이 증진되고, 강화된 총 페놀릭스와 총 플라보노이드스 함량을 가져서 우수한 항산화 활성, 항당뇨 활성 및 항비만 활성을 갖고, 휴대와 섭취가 편리한 스틱 용기용 액상 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a liquid composition for a stick-type container comprising an active wild ginseng extract with enhanced human absorption-type ginsenoside and a method for manufacturing the same, and more particularly, to a human-absorbable ginsenoside Rd2, including an active wild ginseng extract, A liquid composition for a stick container with improved content of F2, Rg3 and compound K, and excellent antioxidant activity, anti-diabetic activity and anti-obesity activity due to enhanced total phenolics and total flavonoids content, and its It relates to a manufacturing method.
삼(Ginseng)은 재배환경에 따른 인위적인 성장과 자연적인 성장의 차이와 형태학적 차이 등에 따라 인삼(人蔘), 산삼(山蔘), 또는 산양삼(山羊蔘)으로 구분한다. 특히 산양삼은 오가피과에 속하며 다년생 초목인 인삼(Panax ginseng)이 산간의 삼림하의 야생상태에서 자연적으로 성장한 산삼의 씨앗이나 유삼을 인위적으로 산에서 재배한 것을 말하며 이들을 산양삼이라 한다. 또한 예로부터 야생에서 자생한 산삼은 최고의 산삼으로 쳤으며 장뇌삼이라고도 불린다. 인삼의 경우에는 대부분 노두(머리 부분)가 3-7개 정도이나 산양삼은 연령에 따라 그 이상인 것이 많으며 인삼의 뿌리는 굵고 짧으나 산양삼은 길고 가늘다. 산양삼은 여러 효능면에서 재배 인삼보다 효과가 더 높은 것으로 알려져 있으나 이를 뒷받침 할 수 있는 과학적 근거가 인삼에 비해 그리 많지는 않은 것은 현 실정이다. Ginseng is classified into ginseng (人蔘), wild ginseng (山蔘), or wild ginseng (山羊蔘) according to the difference between artificial and natural growth according to the cultivation environment and the difference in morphology. In particular, wild ginseng belongs to the family Ogapidae and refers to the artificially grown wild ginseng seeds or yusams grown in the mountains by Panax ginseng , a perennial plant, in the wild under the forest in the mountains, and these are called wild ginseng. In addition, wild ginseng grown in the wild from ancient times has been hit as the best wild ginseng and is also called camphor ginseng. Most of ginseng has 3-7 outcrops, but wild ginseng is more than that depending on age. The roots of ginseng are thick and short, but wild ginseng is long and thin. Wild ginseng is known to be more effective than cultivated ginseng in terms of various efficacy, but there is not much scientific evidence to support it than ginseng.
사포닌은 식물계에 널리 분포하고 있는 트리텔펜과 스테로이드계 배당체 화합물의 총칭이다. 사포닌의 뜻은 라틴어의 sapo(비누)에서 유래되어 이것을 물과 함께 진탕하면 거품을 형성하는 천연계면활성제이다. 삼의 사포닌인 진세노사이드(ginsenoside)를 함유한 산양삼은 한약처방전에서 천연 자연 산삼 다음으로 효능을 높이 평가하고 있다. 또한 재배인삼과 비교시 진세노사이드 함량이 높다고 보고되어져 있으며 재배된 인삼보다 효능 또한 뛰어남이 알려져 있다. 그러나 알려진 산양삼 관련 가공품들은 진세노사이드 함유량이 기준치 미달이거나 인체 흡수형 진세노사이드는 거의 함유되어 있지 않은 실정이다. 종래 효소를 이용하여 인삼에 포함된 진세노사이드를 인체 흡수형으로 전환하는 기술들이 몇몇 개발되어 있으나 (등록특허 10-1751305호), 이들 기술은 비용이 높거나 인체 흡수형 진세노사이드의 증진률이 낮은 문제를 내포하고 있어서, 여전히 인체 흡수형 진세노사이드가 증진된 삼 가공품의 개발이 요구되고 있는 실정이다.Saponin is a generic term for tritelfen and steroid-based glycoside compounds that are widely distributed in the plant world. The meaning of saponin is derived from the Latin word sapo (soap), and it is a natural surfactant that forms bubbles when shaken with water. Sanyangsam, which contains ginsenoside, the saponin of ginseng, is highly evaluated for its efficacy after natural wild ginseng in herbal medicine prescriptions. In addition, it has been reported that the content of ginsenosides is higher than that of cultivated ginseng, and it is known to be superior to cultivated ginseng. However, known processed products related to wild ginseng do not contain ginsenosides or ginsenosides that are absorbed by the human body. Conventionally, some technologies for converting ginsenosides contained in ginseng into human absorption type using enzymes have been developed (Registration Patent No. 10-1751305), but these technologies are expensive or increase rate of human absorption type ginsenosides. Because of this low problem, there is still a demand for the development of a hemp product with improved human absorption-type ginsenosides.
홍삼은 항암, 혈압강하 작용, 뇌신경세포 보호작용, 항혈전 작용 및 항산화 작용이 있다고 알려져 있으나, 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이 (compound K) 같은 인체 흡수형의 유용성분이 열에 의해 소량만 생성되어 그 작용에 한계가 있어서, 이을 증진시킬 수 있도록 다른 성분과의 조합 이용이 연구되고 있다.Red ginseng is known to have anticancer, blood pressure lowering, cranial nerve cell protection, antithrombosis, and antioxidant effects, but only a small amount of useful components absorbed by the human body such as ginsenosides Rd2, F2, Rg3 and compound K It is produced and has a limitation in its action, so the use of combinations with other ingredients is being studied to enhance this.
도라지(Platycodon grandiflorum)는 한국, 중국 동북부, 일본에 자생하며 햇볕이 잘 드는 산야의 초원에서 자라는 다년초이다. 도라지의 뿌리는 식용채소 또는 약용으로 이용되어 왔으며, 뿌리를 물로 씻어 말리거나 껍질을 벗겨서 말리고 건조시킨 것을 길경근이라고 하며 약용한다. 뿌리에는 2%의 트리텔페노이드 사포닌(triterpenoid saponin) 및 0.03%의 스테롤(sterol)이 함유되어 있다. 그 외 당류로서는 이눌린(inulin), 플라티코디닌이 함유되어 있다. 한방에서 도라지의 주요 효능은 기침, 가래 등과 폐의 장해와 밀접한 인후통, 실음(失音), 배뇨곤란, 설사, 후중(後重) 등의 증상에 좋은 것으로 알려져 있다. Bellflower ( Platycodon grandiflorum ) is a perennial plant that grows wild in Korea, northeastern China, and Japan, and grows in the grasslands of sunny mountains. The roots of bellflower have been used for edible vegetables or medicinal purposes, and the roots are washed and dried with water or peeled and dried and dried. Roots contain 2% triterpenoid saponin and 0.03% sterol. Other saccharides include inulin and platicodinin. The main effect of bellflower in oriental medicine is known to be good for symptoms such as coughing, phlegm, and other lung disorders and close sore throat, dysentery, difficulty urinating, diarrhea, and after-jung (後重).
흑마늘은 마늘(Allium sativum for. Pekinense MAKINO)을 발효, 숙성시킨 것으로, 생마늘에 존재하지 않는 S-allylcysteine(SAC)과 S-allyl-mercapto-cysteine이라는 수용성의 황-아미노산이 생성되어 암 예방, 동맥경화 개선, 심장질환의 예방 등의 다양한 약리작용의 효과가 생마늘보다 높은 것으로 알려져 있다. Black garlic is garlic ( Allium sativum for. Pekinense MAKINO) is fermented and aged, and water-soluble sulfur-amino acids called S-allylcysteine (SAC) and S-allyl-mercapto-cysteine, which are not present in raw garlic, are produced to prevent cancer, improve arteriosclerosis, and prevent heart disease. It is known that the effect of various pharmacological actions is higher than that of raw garlic.
이에 본 발명자들은 종래 기술의 요구에 부응하기 위해 연구를 지속한 결과, 산양삼을 특정 조건의 고온숙성을 거치도록 하여 제조한 활성산양삼 추출액과, 홍삼 농축액, 도라지 농축액, 흑마늘 농축액, 벌꿀을 포함하는 액상 조성물은 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이 함량이 현저히 증진되고, 우수한 항산화 활성, 항당뇨 및 항비만 활성을 갖고, 휴대와 섭취가 편리한 스틱형 용기에 적용하기에 적합하다는 것을 확인하고 본 발명을 완성하게 되었다.Accordingly, as a result of continuing research to meet the requirements of the prior art, the inventors of the present invention resulted in a liquid containing active wild ginseng extract, red ginseng concentrate, bellflower concentrate, black garlic concentrate, and honey prepared by subjecting wild ginseng to high-temperature aging under specific conditions. The composition has markedly improved human absorption-type ginsenosides Rd2, F2, Rg3 and compound K content, has excellent antioxidant activity, anti-diabetic and anti-obesity activity, and is suitable for use in stick-type containers that are convenient to carry and ingest. Confirmed and completed the present invention.
따라서 본 발명의 목적은 활성산양삼 추출액, 홍삼 농축액, 도라지 농축액, 흑마늘 농축액, 벌꿀을 포함하여, 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이 함량이 현저히 증진되고, 우수한 항산화 활성, 항당뇨 및 항비만 활성을 갖고, 휴대와 섭취가 편리한 스틱형 용기용 액상 조성물을 제공하는 것이다.Therefore, the object of the present invention is to significantly improve the content of ginsenosides Rd2, F2, Rg3 and compound K absorbed by the human body, including active wild ginseng extract, red ginseng concentrate, bellflower concentrate, black garlic concentrate, and honey, excellent antioxidant activity, antidiabetic And it has anti-obesity activity, to provide a liquid composition for a stick-type container that is convenient to carry and ingest.
본 발명의 또 다른 목적은 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이 함량이 현저히 증진되고, 우수한 항산화 활성, 항당뇨 및 항비만 활성을 갖고, 휴대와 섭취가 편리한 스틱형 용기용 액상 조성물의 제조방법을 제공하는 것이다.Another object of the present invention is a liquid for a stick-type container that is easy to carry and ingest, which significantly enhances the human body absorption type ginsenosides Rd2, F2, Rg3 and compound K content, has excellent antioxidant activity, anti-diabetic and anti-obesity activity. It is to provide a method for preparing the composition.
본 발명의 또 다른 목적은 상기 액상 조성물을 포함하는 항산화 활성, 당뇨 및 비만 개선 및 예방 기능성을 갖는 식품을 제공하는 것이다.Another object of the present invention is to provide a food having antioxidant activity, diabetes and obesity improvement and prevention functions comprising the liquid composition.
상기 목적을 달성하기 위하여, 본 발명은 활성산양삼 추출액 15~25 부피%, 홍삼 농축액 15∼25 부피%, 도라지 농축액 15∼25 부피%, 흑마늘 농축액 4∼6 부피%, 벌꿀 6~12 부피%, 액상 덱스트린 15~20 부피%, 및 나머지 물을 포함하고, 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 증진된 스틱형 용기용 액상 조성물을 제공하는 것이다.In order to achieve the above object, the present invention provides active wild ginseng extract 15-25 vol%, red ginseng concentrate 15-25 vol%, bellflower concentrate 15-25 vol%, black garlic concentrate 4-6 vol%, honey 6-12 vol%, It is to provide a liquid composition for a stick-type container containing 15 to 20% by volume of liquid dextrin, and the rest of water, and enhanced human body absorption ginsenosides Rd2, F2, Rg3 and compound K.
<활성산양삼 추출액><Active wild ginseng extract>
본 발명에서 산양삼은 「산지관리법」제2조 제1호에서 정의하고 있는 산지에서 차광막 등 인공시설을 설치하지 아니하고 생산되는 삼을 칭하는 것으로, 바람직하게는 3년근에서 5년근 사이 재배된 것을 사용한다.In the present invention, wild ginseng refers to ginseng produced without installing artificial facilities such as a light shield in the mountain area defined in
본 발명에서 '활성산양삼'은 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이의 함량이 증진되도록 산양삼을 가공한 것을 말한다. In the present invention, "active wild ginseng" refers to processed wild ginseng so that the contents of human absorbable ginsenosides Rd2, F2, Rg3 and compound K are increased.
본 발명에서 '증숙(steaming process)'은 100℃에서 30~60분간 수증기로 찌는 것을 의미한다. In the present invention,'steaming process' means steaming with water vapor at 100°C for 30 to 60 minutes.
증숙시간이 30분 미만인 경우 충분한 증숙이 진행되지 않아 숙성과 같은 후속 단계가 원활하지 않을 수 있고 잡균의 오염이 발생될 수 있으며, 60분 초과하여 증숙될 경우는 오랜 열처리로 산양삼의 생리활성성분이 파괴될 수 있다.If the steaming time is less than 30 minutes, sufficient steaming may not proceed and subsequent steps such as ripening may not be smooth, and contamination of various germs may occur.If steaming for more than 60 minutes, the physiologically active ingredients of wild ginseng will be reduced by long heat treatment. It can be destroyed.
본 발명에서 '고온숙성'은 70~90℃에서 2∼4일간 유지하는 것을 의미한다.In the present invention,'high temperature aging' means maintaining at 70 to 90°C for 2 to 4 days.
숙성온도가 70℃ 미만이거나 숙성기간이 2일 미만인 경우 숙성이 원활히 이루어지지 않으며, 숙성온도가 90℃ 초과하거나 숙성기간이 4일 초과의 경우 생산된 생리활성물질이 분해되어 함량이 감소될 수 있다.If the aging temperature is less than 70℃ or the aging period is less than 2 days, the aging does not proceed smoothly. If the aging temperature is more than 90℃ or the aging period is more than 4 days, the produced physiologically active substance may be decomposed and the content may be reduced. .
본 발명에서 활성산양삼은 상기와 같은 증숙과 고온숙성을 3회 반복하여 제조될 수 있다. In the present invention, the active wild ginseng can be prepared by repeating the above steaming and high temperature aging three times.
본 발명에서 '활성산양삼 추출액'은 상기와 같이 제조된 활성산양삼을 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화한 후, 활성산양삼 분말에 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출한 후 여과하여 고형분 함량이 10%이상 되도록 농축하여 제조될 수 있다.In the present invention, the'active wild ginseng extract' is powdered to 100 mesh or less after drying the active wild ginseng prepared as described above at 50 to 55°C for 2 to 3 days, and then 10 to 20 times (v/w) in the active wild ginseng powder. ) It can be prepared by adding water and extracting at 80-100° C. for 5-10 hours, then filtering and concentrating so that the solid content is 10% or more.
본 발명에 따른 활성산양삼 추출액은 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이의 함량이 2.77 mg/㎖ 이상, 1.27 mg/㎖ 이상, 1.03 mg/㎖ 이상 및 2.13 mg/㎖ 이상으로, 가공 전에 비하여, 각각 약 1.5배 이상, 4배 이상, 2.8배 이상과 4.2배 이상 증진된다 (표 1).The active wild ginseng extract according to the present invention contains ginsenosides Rd2, F2, Rg3 and compound K of 2.77 mg/ml or more, 1.27 mg/ml or more, 1.03 mg/ml or more, and 2.13 mg/ml or more, compared to before processing. , Respectively, about 1.5 times or more, 4 times or more, 2.8 times or more and 4.2 times or more, respectively (Table 1).
본 발명에 따른 액상 조성물에서, 활성산양삼 추출액은 15~25 부피%로 포함되며, 활성산양삼 추출액이 15 부피% 미만 첨가시 인체 흡수형 진세노사이드 함량이 적어 생리활성이 미흡하며, 25 부피% 초과로 첨가시 산양삼 원료의 고가로 인해 제품의 단가가 상승할 뿐만 아니라 진세노사이드 함량이 높아 인체에 독성이 유발될 수도 있다.In the liquid composition according to the present invention, the active wild ginseng extract is contained in an amount of 15 to 25% by volume, and when the active wild ginseng extract is added less than 15% by volume, the physiological activity is insufficient due to the small amount of human absorbable ginsenoside, and exceeds 25% by volume. When added, the cost of the product increases due to the high cost of raw materials for wild ginseng, and the high ginsenoside content may cause toxicity to the human body.
<홍삼, 도라지, <Red ginseng, bellflower, 흑마늘의Black garlic 농축액> Concentrate>
본 발명에서 홍삼 농축액은 고형분이 10% 이상인 것을 사용한다. In the present invention, the red ginseng concentrate is used having a solid content of 10% or more.
홍삼 농축액은 홍삼근 및/또는 홍미삼 분말에 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출한 후 여과하여 고형분 함량이 10%이상 되도록 농축하여 제조하거나, 상업적으로 용이하게 입수할 수도 있다. Red ginseng concentrate is prepared by adding 10-20 times (v/w) to red ginseng root and/or red rice ginseng powder, extracting for 5-10 hours at 80-100°C, filtering, and concentrating so that the solid content is 10% or more, or commercially easy You can also get it.
바람직하게는 홍삼 농축액은 진세노사이드 Rg1, Rg2 및 Rg3의 합 4.5 mg/g 이상인 것을 사용한다. Preferably, the red ginseng concentrate is used in which the sum of ginsenosides Rg1, Rg2 and Rg3 is 4.5 mg/g or more.
본 발명에 따른 액상 조성물에서, 홍삼 농축액은 15~25 부피%로 포함되며, 홍삼 추출액 15 부피% 미만 첨가시 진세노사이드 함량이 미흡하며, 25 부피% 초과 첨가시 진세노사이드 함량이 높아 인체에 독성이 유발될 수 있다. In the liquid composition according to the present invention, the red ginseng concentrate is contained in an amount of 15 to 25% by volume, and when less than 15% by volume of red ginseng extract is added, the ginsenoside content is insufficient, and when it is added in excess of 25% by volume, the ginsenoside content is high. Toxicity may be caused.
도라지 농축액은 건조 도라지 분말에 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출한 후 여과하여 추출액을 그대로 사용하거나 고형분 함량이 5%이상 되도록 농축하여 제조하거나, 상업적으로 용이하게 입수할 수도 있다. Bellflower concentrate is prepared by adding 10 to 20 times (v/w) to dry bellflower powder, extracting at 80 to 100°C for 5 to 10 hours, then using the extract as it is or concentrating so that the solid content is 5% or more, or It can also be easily obtained commercially.
본 발명에 따른 액상 조성물에서, 도라지 농축액은 15~25 부피%로 포함되며, 도라지 추출액 15 부피% 미만 첨가시 생리활성이 미흡하며, 25 부피% 초과 첨가시 도라지 특유의 향과 맛으로 기호성에 영향을 미칠 수 있다.In the liquid composition according to the present invention, the bellflower concentrate is contained in 15 to 25% by volume, and when less than 15% by volume of the bellflower extract is added, the physiological activity is insufficient, and when it is added in excess of 25% by volume, the palatability is influenced by the characteristic flavor and taste of bellflower. Can be crazy.
흑마늘 농축액은 고온숙성에 제조된 흑마늘에 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출한 후 여과하여 추출액을 그대로 사용하거나 고형분 함량이 5%이상 되도록 농축하여 제조하거나, 상업적으로 용이하게 입수할 수도 있다.Black garlic concentrate is prepared by adding 10-20 times (v/w) to black garlic prepared by high temperature aging, extracting it at 80-100°C for 5-10 hours, and then using the extract as it is by filtration or concentrating so that the solid content is 5% or more. Or, it can be easily obtained commercially.
본 발명에 따른 액상 조성물에서, 흑마늘 농축액은 4∼6 부피%로 포함되며, 흑마늘 추출액 4 부피% 미만 첨가시 생리활성이 미흡하며, 6 부피% 초과 첨가시 흑마늘 특유의 향과 맛으로 기호성에 영향을 미칠 수 있다.In the liquid composition according to the present invention, the black garlic concentrate is contained in 4-6% by volume, and when less than 4% by volume of the black garlic extract is added, the physiological activity is insufficient, and when it is added over 6% by volume, the taste and taste of black garlic affect palatability. Can be crazy.
<스틱형 용기용 액상 조성물 제조> <Preparation of liquid composition for stick type container>
활성산양삼 추출액 15~25 부피%, 홍삼 농축액 15∼25 부피%, 도라지 농축액 15∼25 부피%, 흑마늘 농축액 4∼6 부피%, 벌꿀 6~12 부피%, 액상 덱스트린 15~20 부피%와 나머지 물을 혼합하여, 스틱형 용기에 충진한다. Active wild ginseng extract 15-25% by volume, red ginseng concentrate 15-25% by volume, bellflower concentrate 15-25% by volume, black garlic concentrate 4-6% by volume, honey 6-12% by volume, liquid dextrin 15-20% by volume and rest water Is mixed and filled into a stick-shaped container.
본 발명에서 '벌꿀'은 6~12 부피%로 첨가하여 혼합한다. 벌꿀을 6 부피% 미만으로 포함되는 경우는 묽은 액상으로 섭취가 불편하며, 12 부피% 초과로 포함되는 경우 단맛이 강할 수가 있다. In the present invention,'honey' is added and mixed in an amount of 6 to 12% by volume. If less than 6% by volume of honey is contained, it is inconvenient to consume as a dilute liquid, and if it is contained in more than 12% by volume, the sweet taste may be strong.
본 발명에서 '액상 덱스트린'은 15~20 부피%로 첨가하여 혼합한다. 액상 덱스트인을 15 부피% 미만으로 포함되는 경우는 묽은 액상으로 섭취가 불편하며, 20 부피% 초과로 포함되는 경우 역시 농축 액상으로 섭취가 불편하다. In the present invention,'liquid dextrin' is added and mixed in an amount of 15 to 20% by volume. If the liquid dextine is contained in an amount of less than 15% by volume, it is inconvenient to intake as a dilute liquid.
필요에 따라서, 본 발명의 액상 조성물은 과일 농축액, 한약재 농축액, 감미료(아스파탐, 스테비아 등)를 추가로 포함할 수 있다. If necessary, the liquid composition of the present invention may further contain a fruit concentrate, a herbal medicine concentrate, and a sweetener (aspartame, stevia, etc.).
본 발명에서 '충진'은 당업계에서 알려진 통상의 방법으로 수행될 수 있다.In the present invention,'filling' may be performed by a conventional method known in the art.
본 발명에 따른 액상 조성물은 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이의 함량이 각각 0.08 mg/㎖, 0.12 mg/㎖, 0.08 mg/㎖ 및 0.50 mg/㎖로, 비교예에 비하여, 각각 약 2배 이상, 3배 이상, 1.5배 이상과 2.7배 이상 증진된다 (표 3).In the liquid composition according to the present invention, the contents of ginsenosides Rd2, F2, Rg3 and compound K are 0.08 mg/ml, 0.12 mg/ml, 0.08 mg/ml and 0.50 mg/ml, respectively, compared to the comparative example, respectively, about It is improved more than 2 times, more than 3 times, more than 1.5 times and more than 2.7 times (Table 3).
또한 본 발명에 따른 액상 조성물은 페놀릭스 및 플라보노이드스의 함량이 강화되어 우수한 항산화 활성을 갖고 우수한 알파-글루코시다제 저해활성과 췌장-라이파아제 저해활성도 가져서 항당뇨 활성 및 항비만 활성도 현저히 증진되고 (도 3, 도 4, 표 6), 스틱형 용기에 충진하고 섭취가 용이한 정도의 농도(점도)를 가진다. In addition, the liquid composition according to the present invention has excellent antioxidant activity due to the enhanced content of phenolics and flavonoids, and has excellent alpha-glucosidase inhibitory activity and pancreatic-lipase inhibitory activity, so that antidiabetic activity and antiobesity activity are significantly enhanced. (Fig. 3, Fig. 4, Table 6), it has a concentration (viscosity) of a degree that is easily ingested and filled in a stick-shaped container.
본 발명의 또 다른 목적에 따라서, 본 발명은 According to another object of the present invention, the present invention
ⅰ) 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복하여 활성산양삼을 제조하는 단계; Ⅰ) preparing active wild ginseng by repeating the steaming of wild ginseng at 100°C for 30 to 60 minutes and high-temperature aging for 2 to 4 days at 70 to 90°C for 3 times;
ⅱ) 활성산양삼을 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화하고, 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출하고 여과하여 고형분 함량이 10%이상 되도록 농축하여 활성산양삼 농축액을 제조하는 단계; 및 Ii) After drying the activated wild ginseng for 2 to 3 days at 50 to 55°C, powder it to less than 100 mesh, add 10 to 20 times (v/w), extract for 5 to 10 hours at 80 to 100°C, and filter. Preparing an active wild ginseng concentrate by concentrating so that the solid content is 10% or more; And
ⅲ) 활성산양삼 추출액 15~25 부피%, 홍삼 농축액 15∼25 부피%, 도라지 농축액 15∼25 부피%, 흑마늘 농축액 4∼6 부피%, 벌꿀 6~12 부피%, 액상 덱스트린 15~20 부피% 및 나머지 물을 혼합하여 스틱형 용기에 충진하는 단계를 포함하여 이루어지는 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 증진되고, 우수한 항산화 활성 및 증진된 항당뇨 및 항비만 활성을 갖는 스틱형 용기용 액상 조성물의 제조방법을 제공한다. Iii) 15 to 25 vol% of active wild ginseng extract, 15 to 25 vol% of red ginseng concentrate, 15 to 25 vol% of bellflower concentrate, 4 to 6 vol% of black garlic concentrate, 6 to 12 vol% of honey, 15 to 20 vol% of liquid dextrin, and Stick-type with improved human absorption-type ginsenosides Rd2, F2, Rg3 and Compound K, including the step of mixing the remaining water and filling it into a stick-shaped container, and having excellent antioxidant activity and enhanced antidiabetic and antiobesity activity It provides a method for producing a liquid composition for a container.
단계 ⅰ): Step i): 활성산양삼Active wild ginseng 제조 Produce
활성삼양삼 추출액 제조공정은 상기에 기재된 바와 같다. The manufacturing process of the active samyangsam extract is as described above.
산양삼은 3년근의 산양삼을 수세하여 물기를 제거하여 제공한다.Sanyangsam is provided by washing three-year-old wild ginseng with water to remove moisture.
증숙은 100℃에서 30~60분간 수행하며, 통상의 찜기와 같은 증숙기를 사용하여 수행할 수 있다. Steaming is performed at 100°C for 30 to 60 minutes, and can be performed using a steamer such as a conventional steamer.
증숙된 산양삼의 고온숙성시 개방용기를 사용하여 수분이 증발되게 하거나, 밀폐용기를 사용하여 수분이 증발되지 않게 하여 수행할 수 있다.When the steamed wild ginseng is aged at a high temperature, it can be carried out by allowing moisture to evaporate using an open container or using a closed container to prevent moisture from evaporating.
단계 ⅱ) Step ii) 활성산양삼Active wild ginseng 추출액 제조 Extract preparation
활성산양삼 추출액의 제조공정은 상기에 기재된 바와 같다.The manufacturing process of the active wild ginseng extract is as described above.
여과는 2 ~ 8 mm 여과필터로 여과하며, Filtration is performed with a 2 to 8 mm filter filter,
농축은 열을 가하는 열 농축 방법 혹은 감압 농축 방법으로 고형분 함량이 10% 이상 되게 한다. Concentration is a thermal concentration method that applies heat or a vacuum concentration method so that the solid content is 10% or more.
ⅲ) 액상 조성물 제조Iii) Preparation of liquid composition
활성산양삼 추출액 15~25 부피%, 홍삼 농축액 15∼25 부피%, 도라지 농축액 15∼25 부피%, 흑마늘 농축액 4∼6 부피%, 벌꿀 6~12 부피%, 액상 덱스트린 15~20 부피% 및 나머지 물을 혼합하여 스틱형 용기에 충진한다.Active wild ginseng extract 15-25% by volume, red ginseng concentrate 15-25% by volume, bellflower concentrate 15-25% by volume, black garlic concentrate 4-6% by volume, honey 6-12% by volume, liquid dextrin 15-20% by volume and rest water Mix and fill in a stick-shaped container.
혼합은 상기의 재료들을 교반 혼합기를 사용하여 당업계에서 알려진 통상의 방법으로 수행될 수 있다.Mixing can be carried out by a conventional method known in the art using a stirring mixer.
충진은 스텐드 스틱충진기를 사용하는 방법으로 당업계에서 알려진 통상의 방법으로 수행될 수 있다.Filling may be performed by a conventional method known in the art by using a stand stick filling machine.
필요에 따라서, 본 발명의 제조방법은 단계 ⅲ)에서, 과일 농축액, 한약재 농축액, 및/또는 감미료(아스파탐, 스테비아 등)를 추가로 혼합할 수 있다. If necessary, in the production method of the present invention, in step iii), a fruit concentrate, a herbal medicine concentrate, and/or a sweetener (aspartame, stevia, etc.) may be further mixed.
본 발명의 제조방법에 의해 제조된 액상 조성물은 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이의 함량이 증진되고, 페놀릭스 및 플라보노이드스의 함량이 강화되어 증진된 항산화 활성, 항당뇨 활성 및 항비만 활성을 갖는다.The liquid composition prepared by the manufacturing method of the present invention has increased contents of ginsenosides Rd2, F2, Rg3 and compound K, and enhanced antioxidant activity, antidiabetic activity and anti-obesity by enhancing the content of phenolics and flavonoids. Have activity
발명의 또 다른 목적에 따라서, 본 발명은 상기 제조방법에 의해 제조된 액상 조성물을 포함하는 항산화 활성, 당뇨 및 비만 개선 및 예방 기능성을 갖는 식품을 제공한다.According to another object of the present invention, the present invention provides a food having antioxidant activity, diabetes and obesity improvement and prevention functions comprising a liquid composition prepared by the above manufacturing method.
본 발명에서 식품은 본 발명의 액상 조성물을 그대로 이용하거나, 음료, 젤리, 캡슐 등의 형태의 제품의 형태로 가공될 수 있다. In the present invention, the food may be processed in the form of a product in the form of a beverage, jelly, capsule, or the like using the liquid composition of the present invention as it is.
본 발명에 따른 활성산양삼 추출액을 포함하는 스틱형 용기용 액상 조성물은 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이의 함량이 현저히 증진되어 있고, 더불어 페놀릭스 및 플라보노이드스의 함량이 강화되고 우수한 항산화 활성, 알파-글루코시다제 저해활성과 췌장-라이파아제 저해활성도 가져서, 항당뇨 활성 및 항비만 활성이 증진되어 기능성 식품·의약품의 소재로 사용될 수 있다. 또한 스틱형 용기용으로 휴대와 섭취가 용이하다. The liquid composition for a stick-type container containing the active wild ginseng extract according to the present invention has significantly improved the content of ginsenosides Rd2, F2, Rg3 and compound K, and the content of phenolics and flavonoids is enhanced and excellent antioxidant activity. , As it has alpha-glucosidase inhibitory activity and pancreas-lipase inhibitory activity, anti-diabetic activity and anti-obesity activity are enhanced, so it can be used as a material for functional foods and drugs. Also, it is easy to carry and ingest as it is for a stick-type container.
본 발명에 따른 제조방법은, 통상의 방법에 비하여, 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이의 함량 현저히 증진된 스틱형 용기용 액상 조성물을 생산케 한다.The manufacturing method according to the present invention makes it possible to produce a liquid composition for a stick-type container with significantly improved contents of ginsenosides Rd2, F2, Rg3 and compound K compared to a conventional method.
본 발명에 따른 기능성 식품은 우수한 항산화 활성, 항당뇨 활성 및 항비만 활성을 가져서, 지방생성 억제효과, 체중 조절, 콜레스테롤 저하, 고지혈증개선, 동맥경화 완화, 당뇨병 완화, 혈액순환 개선, 면역력 개선용으로 사용될 수 있다. Functional food according to the present invention has excellent antioxidant activity, anti-diabetic activity and anti-obesity activity, so as to inhibit adipogenesis, weight control, lower cholesterol, improve hyperlipidemia, alleviate arteriosclerosis, alleviate diabetes, improve blood circulation, and improve immunity. Can be used.
도 1은 본 발명에 따른 활성산양삼 추출액을 포함하는 스틱형 용기용 액상 조성물의 제조공정의 일례를 나타낸다.
도 2는 본 발명에 따른 활성산양삼 추출액을 포함하는 스틱형 용기용 액상 조성물의 진세노사이드 HPLC 크로마토그램을 나타낸 것이다. 도 2a는 비교예의 진세노사이드 HPLC 크로마토그램이며, 도 2b는 실시예의 진세노사이드 HPLC 크로마토그램이다.
도 3는 본 발명에 따른 활성산양삼 추출액을 포함하는 스틱형 용기용 액상 조성물의 항산화 활성을 나타낸 것이다. 도 3a는 DPPH 라디칼 소거활성을 나타내고, 도 3b는 ABTS 라디칼 소거활성을 나타내고, 도 3c는 FRAP 환원력을 나타낸다.
도 4는 본 발명에 따른 활성산양산 추출액을 포함하는 스틱형 용기용 액상 조성물의 소화효소 저해활성을 나타낸 것이다. 도 4a는 알파-글루코시다아제 저해활성을 나타내고, 도 3b는 췌장-라이파아제 저해활성을 나타낸다.1 shows an example of a manufacturing process of a liquid composition for a stick-type container containing the active wild ginseng extract according to the present invention.
Figure 2 shows a ginsenoside HPLC chromatogram of a liquid composition for a stick-type container containing the active wild ginseng extract according to the present invention. 2A is a ginsenoside HPLC chromatogram of a comparative example, and FIG. 2B is a ginsenoside HPLC chromatogram of an example.
Figure 3 shows the antioxidant activity of the liquid composition for a stick-type container containing the active wild ginseng extract according to the present invention. Figure 3a shows the DPPH radical scavenging activity, Figure 3b shows the ABTS radical scavenging activity, Figure 3c shows the FRAP reducing power.
Figure 4 shows the digestive enzyme inhibitory activity of the liquid composition for a stick-type container containing the active acid mass production extract according to the present invention. Figure 4a shows the alpha-glucosidase inhibitory activity, Figure 3b shows the pancreatic-lipase inhibitory activity.
다음의 실시 예를 통해 본 발명이 보다 더 구체적으로 설명된다. 이들 실시 예들은 본 발명을 예시하기 위한 것이며 본 발명의 범위가 이들에 의해 제한되어서는 아니 된다.The present invention will be described in more detail through the following examples. These examples are for illustrative purposes only, and the scope of the present invention should not be limited thereto.
제조예 1: 활성산양삼 추출액 제조Preparation Example 1: Preparation of active wild ginseng extract
경상남도 함양군 서상군 일대에서 3년 이상 재배된 산양삼 10 kg을 흐르는 물에 3회 세척하고 완전히 물기를 제거한 후, 5 kg을 찜기통에 담은 후 100℃에서 60분간 증숙하였다. 증숙된 산양삼을 건조 채반에 담아 수분이 증발되게 하면서 75℃에서 3일간 숙성시켰다. 3일간 숙성되어 건조된 산양삼에 다시 동일한 중량의 수분(수분 함량 약 40%)을 첨가하고 100℃에서 60분간 증숙하고, 75℃에서 3일간 재숙성시켰다. 2회 숙성되어 건조된 산양삼에 다시 동일한 중량의 수분(수분 함량 약 40%)을 첨가하고 100℃에서 60분간 증숙하고 75℃에서 3일간 마지막 숙성시켜 활성산양삼을 완성하였다 (도 1). 10 kg of wild ginseng grown for more than 3 years in the area of Seosang-gun, Hamyang-gun, Gyeongsangnam-do, was washed three times with running water and completely drained, and then 5 kg was put in a steamer and steamed for 60 minutes at 100°C. The steamed wild ginseng was put on a dry tray and aged at 75°C for 3 days while allowing moisture to evaporate. The same weight of wild ginseng that has been aged for 3 days and dried Moisture (moisture content of about 40%) was added, steamed at 100°C for 60 minutes, and re-aged at 75°C for 3 days. The same weight of wild ginseng that has been aged and dried twice Moisture (moisture content about 40%) was added, steamed at 100°C for 60 minutes, and last aged at 75°C for 3 days to complete active wild ginseng (Fig. 1).
제조된 활성산양삼을 50∼55℃에서 2일 건조시킨 후 분쇄기로 100메쉬 이하로 분쇄하여 분말을 제조하였다. 분말 50 g에 10배인 정제수 500 ㎖을 첨가하고 100℃에서 8시간 추출하고 8 mm 여과필터로 여과한 후 여과액을 고형분 함량이 10% 이상 되게 통상적인 열을 가하는 방식으로 농축하여 활성산양삼 추출액 (실시예 1)을 제조하였다.The prepared active wild ginseng was dried at 50-55° C. for 2 days and then pulverized to less than 100 mesh with a grinder to prepare a powder. After adding 500 ml of 10 times purified water to 50 g of the powder, extracting for 8 hours at 100°C, filtering with an 8 mm filtration filter, and concentrating the filtrate by applying conventional heat so that the solid content is 10% or more, Example 1) was prepared.
비교를 위하여, 산양삼을 상기와 동일한 방식으로 건조, 분말화, 추출, 농축하여 산양삼 추출액 (비교예 1)을 제조하여 사용하였다.For comparison, wild ginseng was dried, powdered, extracted, and concentrated in the same manner as above to prepare and use a wild ginseng extract (Comparative Example 1).
<진세노사이드 함량 분석><Analysis of Ginsenoside Content>
상기에서 제조한 실시예 1의 활성산양삼 추출액과 비교예 1의 산양삼 추출액을 각각 0.45㎛ 멤브레인 필터로 여과한 후 분석시료로 사용하였다. The active wild ginseng extract of Example 1 prepared above and the wild ginseng extract of Comparative Example 1 were each filtered through a 0.45 μm membrane filter and used as analysis samples.
진세노사이드 분석은 기능성식품 분석법에 기술된 방법을 변형하여 고압액체크로마토그래피(HPLC, high press liquid chromatograph)로 분석하였다. 분석 컬럼은 TSKgel ODS-100Z을 사용하여 시료주입량 10 ㎕, 온도는 30℃, 측정파장은 203 nm, 유속은 1.0 ㎖/min으로 하였고 이동상으로는 A용액은 HPLC water, B용액은 아세토니트릴을 사용하였다. HPLC 분석 조건은 이동상 용액은 0분때 A용액 81% : B용액 19%로 흘려주고 15분때에는 A용액 80% : B용액 20%로 흘려주고 40분때 A용액 77% : B용액 23%, 42분때 A용액 70% : B용액 30%, 75분때에 A용액 65% : B용액 35%, 80분때에 A용액 30% : B용액 70%, 90분때에 A용액 10% : B용액 90%로 이동상을 흘려주었다. 분석된 실시예 1(활성산양삼 추출액) 및 비교예 1(산양삼 추출액)의 인체 흡수형 진세노사이드 함량은 표 1에 나타내었다.Ginsenoside analysis was performed by high press liquid chromatography (HPLC) by modifying the method described in the functional food analysis method. TSKgel ODS-100Z was used as the analysis column, and the sample injection amount was 10 μl, the temperature was 30°C, the measurement wavelength was 203 nm, and the flow rate was 1.0 ml/min. As the mobile phase, HPLC water was used for solution A and acetonitrile was used for solution B. . As for the HPLC analysis conditions, when the mobile phase solution is 0 minutes, flow A solution 81%: B solution 19%, 15 minutes, A
상기 표 1에 나타낸 바와 같이, 인체 흡수형 진세노사이드 함량을 살펴보면, 실시예 1의 활성산양삼 추출액은 진세노사이드 Rd2가 2.77 mg/㎖, F2가 1.27 mg/㎖, Rg3가 1.03 mg/㎖ 및 컴파운드 케이가 2.13 mg/㎖로 측정되어, 비교예 1의 산양삼 추출액에 비하여 각각 약 1.5배, 4배, 2.8배와 4.2배 이상 증진되었음을 알 수 있다.As shown in Table 1, when looking at the content of ginsenosides absorbed by the human body, the active wild ginseng extract of Example 1 has ginsenoside Rd2 of 2.77 mg/ml, F2 of 1.27 mg/ml, Rg3 of 1.03 mg/ml, and Compound K was measured at 2.13 mg/ml, and it can be seen that, compared to the wild ginseng extract of Comparative Example 1, about 1.5 times, 4 times, 2.8 times, and 4.2 times or more were improved.
제조예Manufacturing example 2: 스틱형 용기용 액상 조성물 제조 2: Preparation of liquid composition for stick-type container
상기 제조예 1에서 제조된 활성산양삼 추출액과 산양삼 추출액을 이용하여 하기 표 2와 같은 배합비율로 혼합하여 액상 조성물을 제조하였다. A liquid composition was prepared by mixing the active wild ginseng extract prepared in Preparation Example 1 and the wild wild ginseng extract at the mixing ratio shown in Table 2 below.
홍삼농축액은 충남 금산군에 소재한 ㈜EFG에 제조한 것이며 (진세노사이드 Rg1, Rg2 및 Rg3의 합 4.5 mg/g이상, 고형분 10% 이상, 홍삼근 70%와 홍미삼 30% 혼합된 것), 도라지 농축액과 흑마늘 농축액도 ㈜EFG에 제조한 것이며, 액상 덱스트린과 벌꿀은 시중에 판매되는 것을 구입하였다.Red ginseng concentrate is manufactured by EFG Co., Ltd. located in Geumsan-gun, Chungnam (the sum of ginsenosides Rg1, Rg2 and Rg3 is 4.5 mg/g or more, solid content is 10% or more, 70% red ginseng root and 30% red ginseng are mixed), bellflower concentrate and Black garlic concentrate was also manufactured by EFG, Inc., and liquid dextrin and honey were purchased on the market.
상기의 재료들을 교반 혼합기를 사용하여 혼합하였고 스텐드 스틱충진기를 사용하여 스틱포장지에 12 ㎖씩 충진하였다.The above materials were mixed using a stirring mixer, and 12 ml each were filled in a stick packaging paper using a stand stick filling machine.
시험예Test example
제조예 2에서 제조된 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물의 인체 흡수형 진세노사이드 함량, 페놀릭스와 플라보노이드스 함량, 항산화 활성, 항당뇨 활성과 항비만 활성, 및 영양성분, 이화학적 특성, 유리아미노산을 분석하였다.Human absorption-type ginsenoside content, phenolics and flavonoids content, antioxidant activity, anti-diabetic activity and anti-obesity activity, and nutritional components of the liquid composition comprising the active wild ginseng extract of Example 2 prepared in Preparation Example 2 Scientific properties and free amino acids were analyzed.
시험예Test example 1. 인체 흡수형 진세노사이드 함량 분석 1. Analysis of human absorbable ginsenoside content
제조예 2에서 제조된 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물과 비교예 2의 산양삼 추출액을 포함하는 액상 조성물의 각각에 대한 인체 흡수형 진세노사이드 함량 분석은 상기 제조예 1에 기술된 방법과 동일하게 HPLC를 사용하여 분석하였고, 그 결과를 도 2와 표 3에 나타냈다. Analysis of the content of human absorbable ginsenosides for each of the liquid composition comprising the active wild ginseng extract of Example 2 prepared in Preparation Example 2 and the liquid composition including the wild ginseng extract of Comparative Example 2 was described in Preparation Example 1. Analysis was performed using HPLC in the same manner as in the method, and the results are shown in FIGS. 2 and 3.
도 2에 나타난 바와 같이, 각각의 액상 조성물은 Rd2, F2, Rg3, 컴파운드 케이의 인체 흡수형 진세노사이드 유도체 4가지 종류가 검출되었다. As shown in FIG. 2, four types of human-absorbable ginsenoside derivatives of Rd2, F2, Rg3, and Compound K were detected in each of the liquid compositions.
표 3에 나타낸 바와 같이, 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물은 산양삼 추출액을 포함하는 액상 조성물(비교예 2)에 비하여 인체 흡수형 진세노사이드 Rd2는 2배, F2는 3배, Rg3는 1.5배 및 컴파운드 케이는 2.7배 이상 증진됨을 확인할 수 있다.As shown in Table 3, the liquid composition containing the active wild ginseng extract of Example 2 was compared to the liquid composition containing the wild ginseng extract (Comparative Example 2), 2 times the amount of ginsenoside Rd2 absorbed by the human body, 3 times the F2, It can be seen that Rg3 is increased by 1.5 times and Compound K is increased by more than 2.7 times.
시험예Test example 2. 총 2. Gun 페놀릭스Phenolics 및 플라보노이드스 함량 분석 And flavonoids content analysis
제조예 2에서 제조된 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물의 총 페놀릭스 및 총 플라보노이드스 함량은 Folin-Denis 및 Davis법으로 측정하였다.The total phenolics and total flavonoids contents of the liquid composition containing the active wild ginseng extract of Example 2 prepared in Preparation Example 2 were measured by the Folin-Denis and Davis methods.
총 페놀릭스 함량은 액상 조성물을 100배 희석하고 이 희석용액 0.5 ㎖와 2N Folin-Ciocalteu 페놀 반응시약 0.5 ㎖를 시험관에 분주하고 25% Na2CO3 용액 0.5 ㎖를 추가적으로 첨가한 후 30℃에서 1시간 발색반응을 진행하였다. 1시간 후 발색된 청색을 분광광도계를 사용하여 750 nm에서 흡광도를 측정하고 갈산을 이용한 표준검량곡선으로부터 그 함량을 산출하여 표 4에 나타내었다. The total phenolics content is determined by the liquid composition. After 100-fold dilution, 0.5 ml of this diluted solution and 0.5 ml of 2N Folin-Ciocalteu phenol reaction reagent were dispensed into a test tube, and 0.5 ml of a 25% Na 2 CO 3 solution was additionally added, followed by color development at 30° C. for 1 hour. The absorbance of the blue color developed after 1 hour was measured at 750 nm using a spectrophotometer, and the content was calculated from a standard calibration curve using gallic acid, and is shown in Table 4.
총 플라보노이드스 함량은 액상 조성물을 100배 희석한 조성물 1 ㎖에 디에틸렌글리콜 1 ㎖를 첨가 및 혼합하고 여기에 1N NaOH 용액 0.01 ㎖를 추가하여 37℃의 수욕상에서 1시간 반응을 진행하였다. 1시간 후 420 nm에서 흡광도를 측정하고 루틴을 이용한 표준검량곡선으로부터 그 함량을 산출하여 표 4에 나타냈다.For the total flavonoid content, 1 ml of diethylene glycol was added to and mixed with 1 ml of the composition obtained by diluting the
표 4에 나타낸 바와 같이, 본 발명의 액상 조성물(실시예 2)의 총 페놀릭스와 총 플라보노이드스 함량은 각각 3.79mg/㎖ 및 1.83mg/㎖로 높게 나타났다.As shown in Table 4, the total phenolics and total flavonoids contents of the liquid composition of the present invention (Example 2) were high at 3.79mg/ml and 1.83mg/ml, respectively.
시험예Test example 3. 항산화 활성 분석 3. Antioxidant activity assay
본 발명에 따른 활성산양삼 추출액을 포함하는 액상 조성물(실시예 2)에 대하여 항산화 효과의 지표인 DPPH, ABTS 및 FRAP 환원력을 측정하여 분석하였다.For the liquid composition (Example 2) containing the active wild ginseng extract according to the present invention was analyzed by measuring DPPH, ABTS and FRAP reducing power, which are indicators of the antioxidant effect.
<DPPH 라디칼 소거활성><DPPH radical scavenging activity>
제조예 2에서 제조된 실시예 2의 액상 조성물을 증류수로 2배, 5배, 10배 희석한 분석시료를 각각 0.2 ㎖와 DPPH 용액(1.5×10-4 M) 0.8 ㎖를 혼합하고 30분간 암실에서 반응시키고 517 nm에서 흡광도를 측정하였다. DPPH 라디칼 소거활성의 음성 대조구는 시료 대신 증류수를 사용하여 동일한 방법으로 수행하여 흡광도의 차이를 다음과 같은 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 3a에 나타내었다: The liquid composition of Example 2 prepared in Preparation Example 2 was diluted 2 times, 5 times, and 10 times with distilled water, respectively 0.2 ml and 0.8 ml of DPPH solution (1.5×10 -4 M) were mixed in the dark for 30 minutes. It was reacted at and absorbance was measured at 517 nm. The negative control of DPPH radical scavenging activity was performed in the same manner using distilled water instead of the sample, and the difference in absorbance was calculated as a percentage (%) by the following equation, and the results are shown in FIG. 3A:
라디칼 소거활성(%) = [1-(음성대조구 흡광도/실험구 흡광도)]×100Radical scavenging activity (%) = [1-(absorbance in negative control/absorbance in experimental area)]×100
도 3a에 도시된 바와 같이, 2배 희석한 액상 조성물은 88.72%로 높은 DPPH 라디칼 소거활성을 나타내고, 특히 10배 희석한 액상 조성물도 60%가 넘는 DPPH 라디칼 소거활성을 나타내었다.As shown in FIG. 3A, the liquid composition diluted 2 times showed a high DPPH radical scavenging activity as 88.72%, and in particular, the liquid composition diluted 10 times showed more than 60% DPPH radical scavenging activity.
<ABTS 라디칼 소거활성><ABTS radical scavenging activity>
ABTS 라디칼 소거활성은 2-azino-bis의 청색을 띤 라디칼의 감소 정도에 따라 항산화 활성을 측정하는 방법이다. 이 방법은 물질의 항산화 활성에 의해 ABTS 양이온이 소거되어 청록색 또는 무색으로 탈색되는 원리로서 탈색 반응이 1분 내에 종료되므로 짧은 시간에 측정이 가능한 장점을 가진다.ABTS radical scavenging activity is a method of measuring antioxidant activity according to the degree of reduction of the blue-colored radicals of 2-azino-bis. This method has the advantage of being able to measure in a short time since the decolorization reaction ends within 1 minute as the ABTS cation is eliminated by the antioxidant activity of the substance and decolorizes to cyan or colorless.
ABTS 라디칼 소거활성 측정은 우선 K2S2O8 시약과 메탄올을 2:1로 섞어 암실에서 16시간 반응시켜 양이온 라디칼을 우선 생성시키고 이를 다시 메탄올로 섞어 732 nm에서 흡광도 수치가 0.8±0.2가 되도록 조절한 ABTS 시약을 사용하였다. To measure ABTS radical scavenging activity, first, K 2 S 2 O 8 reagent and methanol were mixed in a ratio of 2:1 and reacted for 16 hours in a dark room to generate cation radicals first, and then mixed with methanol to obtain an absorbance value of 0.8±0.2 at 732 nm. The adjusted ABTS reagent was used.
구체적으로는 ABTS 시약 0.9 ㎖에 실시예 2의 액상 조성물을 증류수로 2배, 5배, 10배 희석한 분석시료를 각각 0.1 ㎖를 첨가하여 3분간 반응시킨 후 즉시 732 nm에서 흡광도를 측정하였다. 음성 대조구는 시료 대신 증류수를 사용하여 동일한 방법으로 수행하여 흡광도의 차이를 상기 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 3b에 나타내었다.Specifically, 0.1 ml of each of the analysis samples obtained by diluting the liquid composition of Example 2 2 times, 5 times and 10 times with distilled water was added to 0.9 ml of ABTS reagent, reacted for 3 minutes, and the absorbance was immediately measured at 732 nm. The negative control was performed in the same manner using distilled water instead of the sample, and the difference in absorbance was calculated as a percentage (%) by the above equation, and the results are shown in FIG. 3B.
도 3b에 나타낸 바와 같이, 2배 희석한 액상 조성물은 90.08%로 높은 라디칼 소거활성을 나타내고, 특히 10배 희석한 액상 조성물도 75%가 넘는 DPPH 라디칼 소거활성을 나타내었다.As shown in Fig. 3b, the liquid composition diluted 2 times exhibited a high radical scavenging activity of 90.08%, and in particular, the liquid composition diluted 10 times showed DPPH radical scavenging activity of more than 75%.
<FRAP 환원력><FRAP reducing power>
FRAP (ferric reducing antioxidant power) 환원력은 화합물들의 환원력을 측정하는 방법으로, Fe3+이온이 Fe2+이온으로 환원시키는 능력을 흡광도 수치를 이용하여 측정하는 방법이다.FRAP (ferric reducing antioxidant power) is a method of measuring the reducing power of compounds, and is a method of measuring the ability of Fe3+ ions to reduce to Fe2+ ions using absorbance values.
아세테이트 버퍼(30 mM, pH 3.6), TPTZ 시약 (10 mM in 40 mM HCl), 및 FeCl3 용액(20 mM 함유 증류수)을 10:1:1 (v/v/v)의 비율로 혼합하여 FRAP 측정 시약을 조제하여 37℃ 항온기에서 15분간 예비반응시켜 두었다.Acetate buffer (30 mM, pH 3.6), TPTZ reagent (10 mM in 40 mM HCl), and FeCl 3 The solution (distilled water containing 20 mM) was mixed in a ratio of 10:1:1 (v/v/v) to prepare a FRAP measurement reagent, and pre-reacted for 15 minutes in a 37°C incubator.
증류수로 2배, 5배, 10배 희석한 분석시료를 각각 50 ㎕와 FRAP 시약 950 ㎕를 분주하여 37℃에서 15분 반응시키고 595 nm에서 흡광도를 측정하였고 그 결과를 도 3c에 나타냈다.50 µl and 950 µl of FRAP reagent were dispensed, respectively, for analysis samples diluted 2 times, 5 times and 10 times with distilled water, reacted at 37°C for 15 minutes, and absorbance was measured at 595 nm, and the results are shown in FIG.
도 3c에 나타낸 바와 같이, FRAP 환원력은 2배 희석한 경우 1.676으로 높게 나타내고, 특히 10배 희석한 액상 조성물도 0.987의 환원력을 나타내었다.As shown in Fig. 3c, the FRAP reducing power was high as 1.676 when diluted 2 times, and in particular, the liquid composition diluted 10 times showed a reducing power of 0.987.
시험예Test example 4. 4. 항당뇨Antidiabetic 및 And 항비만Anti-obesity 효과 분석 Effect analysis
항당뇨 효과 측정은 지표인 알파-글루코시다아제와 항비만 효과의 지표인 췌장-라이파아제를 사용하여 두 가지 효소 저해활성을 통해 분석하였다. Antidiabetic effect was measured by using two enzyme inhibitory activities using alpha-glucosidase, an indicator, and pancreatic-lipase, an indicator of anti-obesity effect.
<알파-글루코시다아제 저해활성><alpha-glucosidase inhibitory activity>
제조예 2에서 제조된 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물와 비교예 2의 산양삼 추출액을 포함하는 액상 조성물의 각각 50 ㎕, 알파-글루코시다아제 효소(1.0 U/㎖) 50 ㎕, 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37℃에서 10분간 예비반응시켰다. 그리고 나서 인산나트륨 완충용액(pH 6.8)에 녹인 p-NPG (5 mM) 100 ㎕를 첨가하여 다시 37℃에서 10분 반응시켰다. 이 반응액에 Na2CO3 (100 mM) 0.75 ㎖를 첨가해 최종 반응을 정지시킨 후 420 nm에서 흡광도를 측정하고 음성대조구로 증류수를 사용하여 상기 식에 의해 백분율(%)로 산출하였고 도 4a에 나타내었다.50 µl, respectively, of a liquid composition containing the active wild ginseng extract of Example 2 prepared in Preparation Example 2 and the liquid composition including the wild ginseng extract of Comparative Example 2, 50 µl of alpha-glucosidase enzyme (1.0 U/ml), 200 50 µl of an mM sodium phosphate buffer solution (pH 6.8) was mixed and pre-reacted at 37°C for 10 minutes. Then, 100 µl of p-NPG (5 mM) dissolved in sodium phosphate buffer solution (pH 6.8) was added and reacted again at 37°C for 10 minutes. Na 2 CO 3 in this reaction solution After adding 0.75 ml of (100 mM) to stop the final reaction, the absorbance was measured at 420 nm and calculated as a percentage (%) by the above equation using distilled water as a negative control, and is shown in FIG. 4A.
도 4a에 의하면, 본 발명에 따른 액상 조성물(실시예 2, 26.37%)은 5배 희석의 경우 비교예 2(13.7%) 보다 2배 이상 증진된 알파-글루코시다아제 저해활성을 나타냈다. According to FIG. 4A, the liquid composition (Example 2, 26.37%) according to the present invention exhibited an alpha-glucosidase inhibitory activity that was enhanced by 2 times or more compared to Comparative Example 2 (13.7%) when diluted 5 times.
<췌장-라이파아제 저해활성><pancreatic-lipase inhibitory activity>
제조예 2에서 제조된 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물와 비교예 2의 산양삼 추출액을 포함하는 액상 조성물의 각각 50 ㎕, 라이파아제 효소(1.0 U/㎖) 50 ㎕, 및 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37℃에서 10분간 예비반응시켰다. 반응 후 인산나트륨 완충용액에 녹인 p-NPB (5 mM) 100 ㎕를 첨가하여 동일하게 10분간 반응시킨 후 100 mM Na2CO3 0.75 ㎖를 첨가해 반응을 정지시켜 420 nm에서 흡광도를 측정하였다. 음성대조구는 시료 대신에 증류수를 취하였으며 시료용액의 첨가구와 무첨가구 사이의 흡광도 차이를 상기 식에 의해 백분율(%)로 산출하였고 그 결과를 도 4b에 나타냈다. 50 µl, lipase enzyme (1.0 U/ml) 50 µl, and 200 mM, respectively, of the liquid composition containing the active wild ginseng extract of Example 2 prepared in Preparation Example 2 and the liquid composition including the wild ginseng extract of Comparative Example 2 50 µl of sodium phosphate buffer solution (pH 6.8) was mixed and pre-reacted at 37°C for 10 minutes. After the reaction, 100 μl of p-NPB (5 mM) dissolved in sodium phosphate buffer was added and reacted for 10 minutes in the same manner, and then 100 mM Na 2 CO 3 The reaction was stopped by adding 0.75 ml, and absorbance was measured at 420 nm. For the negative control, distilled water was taken instead of the sample, and the difference in absorbance between the added and non-added sample solution was calculated as a percentage (%) by the above equation, and the results are shown in FIG. 4B.
도 4b에 나타낸 바와 같이, 본 발명에 따른 액상 조성물(실시예 2)는 5배 희석한 경우 비교예 2에 비하여 2배 이상 증진된 췌장-라이파아제 저해활성을 나타냈다. As shown in FIG. 4B, when the liquid composition according to the present invention (Example 2) was diluted 5 times, the pancreatic-lipase inhibitory activity was increased by 2 times or more compared to Comparative Example 2.
시험예Test example 5. 이화학적 특성 분석 5. Physicochemical characterization
제조예 2에서 제조된 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물과 비교예 2의 산양삼 추출액을 포함하는 액상 조성물의 이화학적 특성은 pH, 산도, 가용성고형물, 환원당 및 조단백질 함량을 측정하였다.The physicochemical properties of the liquid composition containing the active wild ginseng extract of Example 2 prepared in Preparation Example 2 and the liquid composition including the wild ginseng extract of Comparative Example 2 were measured for pH, acidity, soluble solids, reducing sugar and crude protein content.
pH는 pH 미터기(MP 200, UK)로 측정하였고 산도는 0.1 N NaOH를 사용하여 pH 8.2±0.2까지 중화시켰을 시 소요되는 소비량을 젖산양으로 환산하여 %로 표시하였고, 가용성 고형물 함량은 굴절 당도계를 사용하여 측정하였다. 환원당은 DNS법에 따라 적당히 희석된 각 조성물 0.1 ㎖에 DNS 시약 1 ㎖를 첨가하여 100℃에서 20분 동안 발색시킨 후 급속히 냉각하고 분광광도계를 사용하여 570 nm에서 흡광도를 측정하여 검량선과 비교하였다.The pH was measured with a pH meter (MP 200, UK), and the acidity was expressed in% by converting the consumption amount to the amount of lactic acid when neutralized to pH 8.2±0.2 using 0.1 N NaOH. It was measured using. For reducing sugar, 1 ml of DNS reagent was added to 0.1 ml of each composition appropriately diluted according to the DNS method, followed by color development at 100°C for 20 minutes, then rapidly cooled, and absorbance was measured at 570 nm using a spectrophotometer, and compared with a calibration curve.
수용성 단백질 함량은 biuret법을 통하여 실시하였다. CuSO4·5H2O (황산구리 5수화물) 1.5 g에 KNaC4H4O6·4H2O (주석산칼륨 나트륨) 6.0 g을 500 ㎖의 증류수에 녹이고 10% NaOH 300 ㎖를 가한 후 최종 부피가 1,000 ㎖가 되게끔 정용하여 biuret 시약을 제조하였다. 각각의 액상 조성물 시료 1 g을 시험관에 취하고 여기에 biuret 시약 4 ㎖를 첨가 및 혼합하여 37℃에서 20분간 반응시켰다. 이때 음성대조구는 증류수를 취하여 진행하였으며 20분 반응 후 3분간 원심분리 하여 상등액을 540 nm에서 흡광도를 측정하고 단백질 표준곡선(bovine serum albumin)에 의해 산출된 계산식에 따라 수용성 단백질을 정량하여 표 5에 나타내었다.The water-soluble protein content was measured through the biuret method. To 1.5 g of CuSO 4 5H 2 O (copper sulfate pentahydrate), 6.0 g of KNaC 4 H 4 O 6 4H 2 O (sodium potassium stannate) was dissolved in 500 ml of distilled water, and 300 ml of 10% NaOH was added, and the final volume was 1,000. By diagnosing to be ml, a biuret reagent was prepared. 1 g of each liquid composition sample was taken into a test tube, and 4 ml of a biuret reagent was added and mixed thereto, followed by reaction at 37°C for 20 minutes. At this time, the negative control was carried out by taking distilled water, and after 20 minutes reaction, centrifugation for 3 minutes, the supernatant was measured for absorbance at 540 nm, and the water-soluble protein was quantified according to the calculation formula calculated by the protein standard curve (bovine serum albumin). Indicated.
표 5에 나타낸 바와 같이, pH, 산도, 가용성 고형물 및 환원당 함량은 유사하였으며, 조단백질 함량은 비교예 2(151.36 mg/㎖)가 실시예2(141.21 mg/㎖) 보다 조금 더 높았다.As shown in Table 5, pH, acidity, soluble solids and reducing sugar contents were similar, and the crude protein content was slightly higher in Comparative Example 2 (151.36 mg/ml) than in Example 2 (141.21 mg/ml).
시험예Test example 6. 유리 아미노산 함량 분석 6. Analysis of free amino acid content
유리 아미노산 함량 분석은 자동아미노산분석기(기기명 기입)를 이용하여 분석하였다.Free amino acid content analysis was performed using an automatic amino acid analyzer (indicate the device name).
제조예 2에서 제조된 실시예 2의 활성산양삼 추출액을 포함하는 액상 조성물와 비교예 2의 산양삼 추출액을 포함하는 액상 조성물의 각각 1 ㎖와 증류수 4 ㎖를 섞어 60℃에서 1시간 가수분해를 수행하였다. 여기에 10% 5-술포살리실산 무수물 (Sulfosacylic acid dihyarate) 용액을 1 ㎖씩 첨가하여 혼합한 후 4℃에서 2시간 동안 방치시켜 단백질을 응고시킨 후 원심분리하여 상등액만을 0.45 ㎛ 멤브레인 필터로 여과하고 60℃ 수욕상에서 감압 농축하였다. 이 농축물에 대하여 리튬-시트레이트(lithium-citrate, pH 2.2) 버퍼 2 ㎖에 완전히 용해시키고 0.45 ㎛ 멤브레인 필터로 다시 여과하여 자동 아미노산 분석기로 함량을 분석하였고, 그 결과를 표 6에 나타냈다. 1 ml of the liquid composition including the active wild ginseng extract of Example 2 prepared in Preparation Example 2 and the liquid composition including the wild ginseng extract of Comparative Example 2 and 4 ml of distilled water were mixed and hydrolyzed at 60° C. for 1 hour. 1 ml of 10% 5-sulfosacylic acid dihyarate solution was added and mixed, and then allowed to stand at 4℃ for 2 hours to coagulate the protein, followed by centrifugation, and only the supernatant was filtered through a 0.45 µm membrane filter. It was concentrated under reduced pressure in a water bath. The concentrate was completely dissolved in 2 ml of lithium-citrate (pH 2.2) buffer, filtered again through a 0.45 μm membrane filter, and analyzed for content by an automatic amino acid analyzer, and the results are shown in Table 6.
상기 표 6의 결과로부터, 대부분의 일반 아미노산와 필수아미노산들은 비교예 2 보다는 실시예 2에서 높은 것으로 나타났고, 실시예 2의 액상 조성물의 유리 아미노산 총 함량이 1998.12 mg/100 ㎖로 나타났다.From the results of Table 6, most of the general amino acids and essential amino acids were found to be higher in Example 2 than in Comparative Example 2, and the total content of free amino acids in the liquid composition of Example 2 was 1998.12 mg/100 ml.
Claims (5)
상기 활성산양삼은 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복하여 제조된 것이고,
상기 활성산양삼 추출액은 활성산양삼을 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화하고, 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출하고 여과하여 고형분 함량이 10%가 되도록 농축하여 제조된 것인
인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 증진된 스틱형 용기용 액상 조성물로,
상기 활성산양삼 추출액은 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이를 각각 2.77 mg/㎖, 1.27 mg/㎖, 1.03 mg/㎖ 및 2.13 mg/㎖의 함량으로 함유하는 것인 액상 조성물.
Active wild ginseng extract 15-25 vol%, red ginseng concentrate 15-25 vol%, bellflower concentrate 15-25 vol%, black garlic concentrate 4-6 vol%, honey 6-12 vol%, liquid dextrin 15-20 vol%, and the rest Contains water,
The active wild ginseng is prepared by steaming wild wild ginseng at 100°C for 30 to 60 minutes and aging the steamed wild wild ginseng at 70 to 90°C for 2 to 4 days 3 times,
The active wild ginseng extract is powdered to 100 mesh or less after drying the active wild ginseng at 50-55°C for 2 to 3 days, added 10-20 times (v/w) and extracted for 5-10 hours at 80-100°C. And then filtered and concentrated to a solid content of 10%.
It is a liquid composition for a stick-type container with enhanced human body absorption ginsenosides Rd2, F2, Rg3 and compound K,
The active wild ginseng extract is a liquid composition containing ginsenosides Rd2, F2, Rg3 and compound K in an amount of 2.77 mg/ml, 1.27 mg/ml, 1.03 mg/ml and 2.13 mg/ml, respectively.
ⅰ) 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복하여 활성산양삼을 제조하는 단계;
ⅱ) 활성산양삼을 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화하고, 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출하고 여과하여 고형분 함량이 10%가 되도록 농축하여 활성산양삼 농축액을 제조하는 단계; 및
ⅲ) 활성산양삼 추출액 15~25 부피%, 홍삼 농축액 15∼25 부피%, 도라지 농축액 15∼25 부피%, 흑마늘 농축액 4∼6 부피%, 벌꿀 6~12 부피%, 액상 덱스트린 15~20 부피% 및 나머지 물을 혼합하여 스틱형 용기에 충진하는 단계를 포함하고,
상기 활성산양삼 추출액은 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이를 각각 2.77 mg/㎖, 1.27 mg/㎖, 1.03 mg/㎖ 및 2.13 mg/㎖의 함량으로 함유하는 것인 제조방법.A method for preparing a liquid composition for a stick-type container with improved human body absorption type ginsenosides Rd2, F2, Rg3 and compound K according to claim 1, wherein the method comprises:
Ⅰ) preparing active wild ginseng by repeating the steamed wild ginseng at 100°C for 30-60 minutes and the steamed wild wild ginseng at 70∼90°C for 2 to 4 days high temperature aging 3 times;
Ii) After drying the activated wild ginseng for 2 to 3 days at 50 to 55°C, powder it to less than 100 mesh, add 10 to 20 times (v/w), extract for 5 to 10 hours at 80 to 100°C, and filter. Concentrating so that the solid content is 10% to prepare an active wild ginseng concentrate; And
Iii) 15 to 25 vol% of active wild ginseng extract, 15 to 25 vol% of red ginseng concentrate, 15 to 25 vol% of bellflower concentrate, 4 to 6 vol% of black garlic concentrate, 6 to 12 vol% of honey, 15 to 20 vol% of liquid dextrin, and Including the step of mixing the remaining water and filling the stick-shaped container,
The active wild ginseng extract contains ginsenosides Rd2, F2, Rg3 and Compound K in amounts of 2.77 mg/ml, 1.27 mg/ml, 1.03 mg/ml and 2.13 mg/ml, respectively.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180122779A KR102150162B1 (en) | 2018-10-15 | 2018-10-15 | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180122779A KR102150162B1 (en) | 2018-10-15 | 2018-10-15 | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200042325A KR20200042325A (en) | 2020-04-23 |
KR102150162B1 true KR102150162B1 (en) | 2020-08-31 |
Family
ID=70472589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180122779A KR102150162B1 (en) | 2018-10-15 | 2018-10-15 | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102150162B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220031147A (en) * | 2020-09-03 | 2022-03-11 | 주식회사 라파데오 | Functional composition for pet and use of thereof |
KR102458937B1 (en) * | 2022-07-15 | 2022-10-25 | 이천 영농조합법인 | Method for producing red ginseng with improved active ingredients and yield |
KR102677837B1 (en) * | 2023-12-19 | 2024-06-24 | 주식회사 에스제이유글로벌 | Red ginseng with increased ginsenoside content and method for manufacturing the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100805852B1 (en) | 2006-12-21 | 2008-02-21 | 한국식품연구원 | Method of producing ginsenoside enforced ginseng and method of producing red ginseng employing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160072802A (en) * | 2014-12-15 | 2016-06-23 | 경성대학교 산학협력단 | Pharmaceutical Composition Including Ginseng Saponin As Active Ingredient |
KR20180007708A (en) * | 2016-07-13 | 2018-01-24 | 농업회사법인 주식회사축복의열매 | Mouthwatering red ginseng liquid for children and manufacturing method thereof |
KR101919687B1 (en) * | 2017-03-07 | 2018-11-19 | 함양군 | Wild Cultivated Ginseng Mixed concentrate and Production method thereof, Production shipment method of Wild Cultivated Ginseng Mixed concentrate liquid stick set |
-
2018
- 2018-10-15 KR KR1020180122779A patent/KR102150162B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100805852B1 (en) | 2006-12-21 | 2008-02-21 | 한국식품연구원 | Method of producing ginsenoside enforced ginseng and method of producing red ginseng employing the same |
Also Published As
Publication number | Publication date |
---|---|
KR20200042325A (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101073370A (en) | Blackthorn pear products and its production | |
KR102150162B1 (en) | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof | |
CN102470155A (en) | Method for producing novel gynostemma pentaphyllum extracts having increased amounts of damulin A and damulin B and pharmaceutical composition for treating metabolic diseases using the same | |
GB2608697A (en) | Polysaccharide-peptide complex for lowering blood sugar, blood lipid and glycosylated hemoglobin levels, and preparation method | |
WO2014185653A1 (en) | Health supplement using dendropanax morbifera lev and method for producing same | |
KR101142373B1 (en) | Material of extract excellent anti-glycosuria effect, preparation method thereof and food comprising thereof | |
KR101774769B1 (en) | Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof | |
KR101253658B1 (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
KR102012872B1 (en) | High concentrate for beverage containing black raspberry, plantaginis asiatica l., schizandra chinensis, lycii fructus and torilis japonica decandolle and the high concentrate for beverage prepared from the same | |
KR101929664B1 (en) | Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof | |
WO2007007994A1 (en) | Food composition for improving liver function comprising a lonicera caerulea l. var. edulis extract | |
CN109770141A (en) | A kind of drink eaten suitable for the high crowd of uric acid | |
KR102132537B1 (en) | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof | |
KR102335208B1 (en) | Immune enhancing liquid composition having increased ginsenosides Rb1, Rg1 and Rg3 and preparation method thereof | |
KR20220087888A (en) | Black bellflower syrup and method of preparing therefor | |
KR20100116919A (en) | Compositions comprising extract from codonopsis lanceolata for preventing or treating obesity, hyperlipidemia or fatty liver | |
US4912089A (en) | Cariostatic materials and foods, and method for preventing dental caries | |
KR101811227B1 (en) | Composition for Immune Enhancement, Fatigue Recovery, Physiologically Active, Detoxification Comprising Extracts of Lycium chinence miller, Rubus coreanus Miq. & Schisandra chinensis | |
KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
KR100266740B1 (en) | Whitening Food Composition | |
KR102660565B1 (en) | Extracted composition of mountain-cultivated ginseng having increased ginsenoside Rg1 and Rb1 and preparation method thereof | |
KR100545407B1 (en) | Food composition for the treatment of the hyperlipidemia and its process | |
KR102410301B1 (en) | Stick-type jelly composition having enriched ginsenoside compound K and catechin and preparation method thereof | |
JPS59106276A (en) | Health food | |
KR101413492B1 (en) | Manufacturing method and makgeolli using red ginseng and lactic acid bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |